Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Akira Furutani is active.

Publication


Featured researches published by Akira Furutani.


Nature Medicine | 2005

Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase.

Koichi Yoshimura; Hiroki Aoki; Yasuhiro Ikeda; Kozo Fujii; Norio Akiyama; Akira Furutani; Yoshinobu Hoshii; Nobuyuki Tanaka; Romeo Ricci; Tokuhiro Ishihara; Kensuke Esato; Kimikazu Hamano; Masunori Matsuzaki

Abdominal aortic aneurysm (AAA) is a common disease among elderly people that, when surgical treatment is inapplicable, results in progressive expansion and rupture of the aorta with high mortality. Although nonsurgical treatment for AAA is much awaited, few options are available because its molecular pathogenesis remains elusive. Here, we identify JNK as a proximal signaling molecule in the pathogenesis of AAA. Human AAA tissue showed a high level of phosphorylated JNK. We show that JNK programs a gene expression pattern in different cell types that cooperatively enhances the degradation of the extracellular matrix while suppressing biosynthetic enzymes of the extracellular matrix. Selective inhibition of JNK in vivo not only prevented the development of AAA but also caused regression of established AAA in two mouse models. Thus, JNK promotes abnormal extracellular matrix metabolism in the tissue of AAA and may represent a therapeutic target.


Circulation | 2005

Regeneration of Infarcted Myocardium by Intramyocardial Implantation of Ex Vivo Transforming Growth Factor-β–Preprogrammed Bone Marrow Stem Cells

Tao-Sheng Li; Masanori Hayashi; Hiroshi Ito; Akira Furutani; Tomoaki Murata; Masunori Matsuzaki; Kimikazu Hamano

Background—Recent studies have shown that bone marrow–derived stem cells differentiate into the phenotype of cardiomyocytes in vivo and in vitro. We tried to regenerate infarcted myocardium by implanting ex vivo transforming growth factor (TGF)-&bgr;–preprogrammed CD117 (c-kit)–positive (CD117+) stem cells intramyocardially. Methods and Results—CD117+ cells were isolated from the bone marrow mononuclear cells of GFP-transgenic or normal C57/BL6 mice. The myogenic differentiation of CD117+ cells was achieved by cultivation with TGF-&bgr;. Using an acute myocardial infarction model, we also tried to regenerate infarcted myocardium by implanting untreated (newly isolated) or preprogrammed (24 hours of cultivation with 5 ng/mL TGF-&bgr;1) CD117+ cells intramyocardially. TGF-&bgr; increased the cellular expression of myosin, troponins, connexin-43, GATA-4, and NKx-2.5, which suggested that it induced the myogenic differentiation of CD117+ cells. Compared with the effects of PBS injection only, the microvessel density in the infarcted myocardium was increased significantly 3 months after the implantation of either TGF-&bgr;–preprogrammed or untreated CD117+ cells. Moreover, many of the TGF-&bgr;–preprogrammed CD117+ cells were stained positively for myosin, whereas few of the untreated CD117+ cells were. Histological analysis revealed newly regenerated myocardium in the left ventricular anterior wall after the implantation of TGF-&bgr;–preprogrammed cells but not untreated cells. Furthermore, the left ventricular percent fraction shortening was significantly higher after the implantation of TGF-&bgr;–preprogrammed cells than after the implantation of untreated CD117+ cells. Conclusions—TGF-&bgr; conducted the myogenic differentiation of CD117+ stem cells by upregulating GATA-4 and NKx-2.5 expression. Therefore, the intramyocardial implantation of TGF-&bgr;–preprogrammed CD117+ cells effectively assisted the myocardial regeneration and induced therapeutic angiogenesis, contributing to functional cardiac regeneration.


Cell Transplantation | 2002

Neovascularization induced by autologous bone marrow cell implantation in peripheral arterial disease.

Kensuke Esato; Kimikazu Hamano; Tao-Sheng Li; Akira Furutani; Atsushi Seyama; Hiroaki Takenaka; Nobuya Zempo

Neovascularization has recently been used as a new treatment for severe ischemic disease. We tried to induce therapeutic neovascularization by autologous bone marrow cell implantation (BMCI) in eight selected patients with chronic peripheral arterial disease (PAD), in whom traditional treatments had failed. Improvement of subjective symptoms was seen in seven patients after treatment. Of three limbs with toe or finger ulceration, complete healing was achieved in two, while the other one became less severe after treatment. No relative toxicity was observed in any of the patients. BMCI might be a feasible treatment for selected patients with chronic PAD.


Annals of the New York Academy of Sciences | 2006

Regression of Abdominal Aortic Aneurysm by Inhibition of c‐Jun N‐Terminal Kinase in Mice

Koichi Yoshimura; Hiroki Aoki; Yasuhiro Ikeda; Akira Furutani; Kimikazu Hamano; Masunori Matsuzaki

Abstract:  Abdominal aortic aneurysm (AAA) is a common disease that, when surgical treatment is inapplicable, results in rupture of the aorta with high mortality. Although nonsurgical treatment for AAA is eagerly awaited, the destruction of the aortic walls in AAA has been considered an irreversible process. We found that c‐Jun N‐terminal kinase (JNK) is highly activated in human AAA walls. We also found that JNK activity is essential for the expression of matrix metalloproteinase (MMP)‐9 and, concurrently, suppression of the extracellular matrix (ECM) biosynthesis. We therefore investigated the role of JNK in the pathogenesis of AAA in vivo. We created a mouse AAA model by periaortic application of CaCl2, which was accompanied by activation of JNK and MMPs, and suppression of lysyl oxidase (LOX), which is an essential biosynthetic enzyme for collagen and elastin fibers. Our data indicate that, in addition to MMP activities, suppression of ECM biosynthesis may contribute to the AAA pathogenesis because local LOX gene delivery prevented AAA formation. Treatment of mice with SP600125, a specific JNK inhibitor, completely abrogated the formation of CaCl2‐induced AAA. Furthermore, SP600125 treatment after the establishment of AAA caused a reduction in the aortic diameters with normalized tissue architecture. SP600125 treatment also caused significant regression of angiotensin II‐induced AAA in ApoE‐null mice after its establishment, as demonstrated by serial ultrasonographic studies in live animals. These data demonstrate that JNK dictates the abnormal ECM metabolism in AAA pathogenesis by enhancing tissue degradation and suppressing tissue repair. Therefore, inhibition of JNK may provide a novel therapeutic option for AAA.


Atherosclerosis | 2010

Lysyl oxidase resolves inflammation by reducing monocyte chemoattractant protein-1 in abdominal aortic aneurysm

Masahiko Onoda; Koichi Yoshimura; Hiroki Aoki; Yasuhiro Ikeda; Noriyasu Morikage; Akira Furutani; Masunori Matsuzaki; Kimikazu Hamano

Lysyl oxidase (LOX) is an enzyme critical for the stability of extracellular matrix and also known to have diverse biological functions. Little is known, however, about the role of LOX in regulating inflammation. Here we demonstrate that LOX suppresses secretion of monocyte chemoattractant protein-1 (MCP-1) in cultured vascular smooth muscle cells. Furthermore, enhancement of LOX activity reduces MCP-1 in a mouse model of abdominal aortic aneurysm (AAA), thereby preventing macrophage infiltration and AAA progression. These findings suggest that LOX has a novel function in resolving inflammation by reducing MCP-1 in AAA.


International Journal of Molecular Sciences | 2015

Inhibitory Effect of Statins on Inflammation-Related Pathways in Human Abdominal Aortic Aneurysm Tissue

Koichi Yoshimura; Ayako Nagasawa; Junichi Kudo; Masahiko Onoda; Noriyasu Morikage; Akira Furutani; Hiroki Aoki; Kimikazu Hamano

HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase inhibitors (statins) have been suggested to attenuate abdominal aortic aneurysm (AAA) growth. However, the effects of statins in human AAA tissues are not fully elucidated. The aim of this study was to investigate the direct effects of statins on proinflammatory molecules in human AAA walls in ex vivo culture. Simvastatin strongly inhibited the activation of nuclear factor (NF)-κB induced by tumor necrosis factor (TNF)-α in human AAA walls, but showed little effect on c-jun N-terminal kinase (JNK) activation. Simvastatin, as well as pitavastatin significantly reduced the secretion of matrix metalloproteinase (MMP)-9, monocyte chemoattractant protein (MCP)-2 and epithelial neutrophil-activating peptide (CXCL5) under both basal and TNF-α-stimulated conditions. Similar to statins, the Rac1 inhibitor NSC23766 significantly inhibited the activation of NF-κB, accompanied by a decreased secretion of MMP-9, MCP-2 and CXCL5. Moreover, the effect of simvastatin and the JNK inhibitor SP600125 was additive in inhibiting the secretion of MMP-9, MCP-2 and CXCL5. These findings indicate that statins preferentially inhibit the Rac1/NF-κB pathway to suppress MMP-9 and chemokine secretion in human AAA, suggesting a mechanism for the potential effect of statins in attenuating AAA progression.


European Surgical Research | 2005

HMG-CoA reductase inhibitors reduce matrix metalloproteinase-9 activity in human varicose veins

S. Nomura; Koichi Yoshimura; Norio Akiyama; A. Mikamo; Akira Furutani; Hiroki Aoki; Masunori Matsuzaki; Kimikazu Hamano

Matrix metalloproteinases (MMPs) have been implicated in tissue degradation in varicose veins. The aim of this study was to investigate the effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) on the activity of MMPs in varicose veins. MMP-9 was present at significantly higher levels in varicose veins than in controls and was localized mainly in smooth muscle cells at the tunica media, where marked degradation of the extracellular matrix was observed. Both simvastatin and pravastatin strikingly suppressed MMP-9 activity in ex vivo culture of varicose veins. Simvastatin suppressed MMP-9 at both the mRNA and protein levels as well as at the urokinase-type plasminogen activator protein level, resulting in the dramatic suppression of MMP-9 activity induced by tumor necrosis factor-α. Therefore, statins suppress MMP-9 activity by multiple mechanisms in varicose veins, suggesting they may have clinical potential for the treatment of this disease.


Journal of Cardiology | 2009

Impact of intraoperative transesophageal echocardiography in cardiac and thoracic aortic surgery: Experience in 1011 cases

Chikage Kihara; Kazuya Murata; Yasuaki Wada; Yasuyuki Hadano; Rikimaru Ohyama; Shinichi Okuda; Takeo Tanaka; Yoshio Nose; Yasuhiro Fukagawa; Hiroko Yoshino; Takehisa Susa; Akihito Mikamo; Akira Furutani; Toshiro Kobayashi; Kimikazu Hamano; Masunori Matsuzaki

BACKGROUND Although intraoperative transesophageal echocardiography (IOTEE) has been widely used in cardiovascular surgery, the exact incidence of abnormalities detected by IOTEE in each type of surgical procedure is still unclear. The aim of this study was to review our experiences of IOTEE, in patients who underwent different types of cardiovascular surgery and to evaluate the clinical usefulness of IOTEE. METHODS AND RESULTS Our database of 1011 consecutive patients, who underwent cardiovascular surgery and IOTEE monitoring was reviewed. The incidence of abnormal findings was 115 of 1011 patients (11.4%), and the highest incidence was the appearance of new wall motion abnormalities after cardiopulmonary bypass. These findings influenced surgical decision-making in 59 of the evaluated 1011 patients (5.8%). CONCLUSIONS IOTEE provides important intraoperative and postoperative information that may influence surgical decision-making in various cardiovascular surgeries.


Annals of the New York Academy of Sciences | 2006

Identification of c‐Jun N‐Terminal Kinase as a Therapeutic Target for Abdominal Aortic Aneurysm

Koichi Yoshimura; Hiroki Aoki; Yasuhiro Ikeda; Akira Furutani; Kimikazu Hamano; Masunori Matsuzaki

Abstract:  Despite the advances in molecular cell biology, identification of a therapeutic target in a given disease still poses a significant challenge. Here we report a strategy for identification of the therapeutic target in abdominal aortic aneurysm (AAA). We screened for various signaling molecules in human AAA samples and identified c‐Jun N‐terminal kinase (JNK) as a prominently activated molecule. The JNK pathway‐oriented transcriptome analyses revealed that activation of JNK leads to enhancement of the activity of matrix metalloproteinases and, concurrently, suppression of the extracellular matrix biosynthesis, suggesting that JNK may represent a novel therapeutic target in AAA.


Surgery Today | 1996

Successful management of a giant spinal arteriovenous malformation with multiple communications between primitive arterial and venous structures by embolization: Report of a case

Takayuki Kuga; Kensuke Esato; Nobuya Zempo; Kentaro Fujioka; Mikihiko Harada; Akira Furutani; Norio Akiyama; Shuji Toyota; Yuji Fujita

A 47-year-old woman was admitted to our hospital with a giant spinal arteriovenous malformation (AVM) causing heart failure and thoracic myelopathy. Angiography revealed that the spinal AVM had multiple feeding vessels branching from the 5th through 12th intercostal arteries. The drainage vein flowed to the azygos vein and superior vena cava. The AVM destroyed the 7th thoracic vertebra. The cardiac output was 16.7l/min and the shunt ratio was 64% before treatment. Embolization with cyanoacrylate was performed because the operation was considered to be associated with a significant risk of paraplegia and organ ischemia. The cardiac output decreased to 11.6l/min and the shunt ratio was reduced to 32%. After embolization the patient demonstrated no symptoms of either heart failure or sensory deficits. During embolization, provocative tests using sodium amytal and lidocaine with magnetic stimulation were also performed. The above findings suggest that provocative tests and magnetic stimulation are useful to predict paraplegia, which could result from embolization while, in addition, embolization is considered to be a useful treatment for multiple shunt and nidus in this region.

Collaboration


Dive into the Akira Furutani's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge